<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">CNS Drug Rev</journal-id><journal-id journal-id-type="iso-abbrev">CNS Drug Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3671</journal-id><journal-id journal-id-type="pmc-domain">cnsdrugrev</journal-id><journal-id journal-id-type="publisher-id">CNS</journal-id><journal-title-group><journal-title>CNS Drug Reviews</journal-title></journal-title-group><issn pub-type="ppub">1080-563X</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6741652</article-id><article-id pub-id-type="pmcid-ver">PMC6741652.1</article-id><article-id pub-id-type="pmcaid">6741652</article-id><article-id pub-id-type="pmcaiid">6741652</article-id><article-id pub-id-type="pmid">12847556</article-id><article-id pub-id-type="doi">10.1111/j.1527-3458.2003.tb00246.x</article-id><article-id pub-id-type="publisher-id">CNS141</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>BP 897, a Selective Dopamine D<sub>3</sub> Receptor Ligand with Therapeutic Potential for the Treatment of Cocaine&#8208;Addiction</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author" corresp="yes"><name name-style="western"><surname>Garcia&#8208;Ladona</surname><given-names initials="FJ">F. J.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr2" contrib-type="author"><name name-style="western"><surname>Cox</surname><given-names initials="BF">B. F.</given-names></name><xref ref-type="aff" rid="a2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="a1">
<label><sup>1</sup></label>Department of Molecular Biology, Neuroscience Research, Abbott GmbH &amp; Co. KG., Ludwigshafen, Germany;</aff><aff id="a2">
<label><sup>2</sup></label>Department of Integrative Pharmacology, Abbott Laboratories, Abbott Park, IL, USA</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Address correspondence and reprint requests to: Dr. F. J. Garcia&#8208;Ladona, Department of Molecular Biology, Neuroscience Research, Abbott GmbH &amp; Co. KG., P.O. Box 210805, D&#8208;67008 Ludwigshafen, Germany. Tel: +49 (621) 589&#8211;1436. Fax: +49 (621) 589&#8211;6&#8211;1436. E&#8208;mail: <email>francisco.javier.garcia-ladona@abbott.com</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>6</month><year>2006</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2003</year></pub-date><volume>9</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">333839</issue-id><issue-id pub-id-type="doi">10.1111/cns.2003.9.issue-2</issue-id><fpage>141</fpage><lpage>158</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2003</year></date></event><event event-type="pmc-live"><date><day>16</day><month>09</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-09-17 00:23:13.520"><day>17</day><month>09</month><year>2019</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CNS-9-141.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CNS-9-141.pdf"/><abstract><title>ABSTRACT</title><p>BP 897 is a potent (<italic toggle="yes">K</italic>
<sub>i</sub>= 0.92 nM) dopamine D<sub>3</sub> receptor compound developed for the treatment of cocaine abuse and craving. BP 897 has a high selectivity for the dopamine D<sub>3</sub> versus D<sub>2</sub> receptors (70&#8208;fold) and a moderate affinity for 5&#8208;HT<sub>1A</sub> receptors, (<italic toggle="yes">K</italic>
<sub>i</sub>= 84 nM), adrenergic&#8208;&#945;1 (<italic toggle="yes">K</italic>
<sub>i</sub>= 60 nM) and &#8208;&#945;<sub>2</sub> adrenoceptors (<italic toggle="yes">K</italic>
<sub>i</sub>= 83 nM). BP 897 displays significant intrinsic activity at the human dopamine D<sub>3</sub> receptor by decreasing forskolin&#8208;stimulated cAMP levels and by stimulating mitogenesis of dopamine D<sub>3</sub>&#8208;expressing NG108&#8211;15 cells. Although these findings suggest that BP 897 is a partial agonist, recent studies in Chinese Hamster Ovary (CHO) cells with expressed dopamine D<sub>3</sub> receptors demonstrated that BP 897 is devoid of any intrinsic activity but potently inhibits dopamine agonist effects (pIC<sub>50</sub>= 9.43 and 9.51) in agonist&#8208;induced acidification rate or increase of GTP&#947;S binding, respectively. In addition, BP 897 inhibits <italic toggle="yes">in vivo</italic> (EC<sub>50</sub>= 1.1 mg/kg, i.v.) agonist&#8208;induced decrease of firing rate of dopaminergic neurons in the substantia nigra.</p><p>It has been clearly shown that BP 897, 1 mg/kg, i.p., reduces cocaine&#8208;seeking behavior in rats, without producing reinforcement on its own. In rhesus monkeys, BP 897 is not self&#8208;administered (up to 30 &#956;g/kg, i.v.) but reduces cocaine self&#8208;administration. The potential usefulness of BP 897 in the treatment of drug&#8208;seeking behavior is further supported by its effects in drug conditioning models. Although BP 897 reduces L&#8208;DOPA&#8208;induced dyskinesia in 1&#8208;methyl&#8208;4&#8208;phenyl&#8208;1,2,3,6&#8208;tetrahydropyridine (MPTP)&#8208;treated monkeys, it provokes a return of parkinsonian symptoms. At high doses BP 897 has been reported to produce catalepsy in rats. Pharmacokinetic and toxicological data have not yet been published. These interesting preclinical findings with BP 897 provide additional validation for dopamine D<sub>3</sub> receptor as a therapeutic target for the treatment of cocaine abuse and its associated central nervous system (CNS) disorders. BP 897 recently entered phase II clinical studies.</p></abstract><kwd-group><kwd id="k1">BP 897</kwd><kwd id="k2">Cocaine</kwd><kwd id="k3">Craving</kwd><kwd id="k4">D<sub>3</sub> receptors</kwd><kwd id="k5">Drug abuse</kwd><kwd id="k6">Withdrawal</kwd></kwd-group><counts><ref-count count="104"/><page-count count="18"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2003</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.9 mode:remove_FC converted:10.09.2019</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>